nature portfolio

Corresponding author(s):	Dugald Reid, Kasper Andersen, Jieshun Lin
Last updated by author(s):	May 17, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

C+	at.	isti	CC
Jι	aι	ıσι	いしこ

n/a	Confirmed
	$oxed{\boxtimes}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	🔀 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection No software was used for data collection

Data analysis

FUN protein sequences were identified by BLAST 2.15.0 and SHOOT 1.1.0 and aligned with MAFFT 7.490 and a tree constructed using FastTree 2.1.11. The tree was visualised using iTOL 6.7.3. RNAseq analysis was performed by mapping reads to the reference transcriptome using Salmon 1.10.1 and quantification performed using DEseq2 1.40.2. Elemental distribution was analysed using PyMca 5.9.2

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

A reporting summary for this article is available as Supplementary Information file. The main data supporting the findings of this study are available within the article, its Extended Data Figures and supplementary information files. RNAseq raw data has been submitted to NCBI under accession PRJNA985805 and processed

data with differential expression statistics is available as supplementary file 1. Source data for each figure are provided as supplementary information files. Full versions of EMSA blots are included in the source data file.

Research involving	human parti	cipants, their	data, or bic	logical	material
--------------------	-------------	----------------	--------------	---------	----------

Policy information abo and sexual orientation		uman participants or human data. See also policy information about sex, gender (identity/presentation), ty and racism.		
Reporting on sex and	d gender not a	pplicable		
Reporting on race, ethnicity, or other socially relevant groupings		pplicable		
Population characteristics not applicable		pplicable		
Recruitment	not a	pplicable		
Ethics oversight	not a	pplicable		
Note that full information	on the approval of	the study protocol must also be provided in the manuscript.		
Field-spec	ific reno	urting		
•	•	pest fit for your research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences				
		oural & social sciences		
Total reference copy of the a	ocament with an secti	ons, see <u>nataleteen veetaments in reporting sammaly national</u>		
Life scienc	es study	/ design		
All studies must disclos	se on these points	s even when the disclosure is negative.		
ex	Sample size was not predetermined. Sample sizes were in line with norms of the field and determined by previous experience in performing experiments of the same technical nature. For each experiment this depended on previous experience with the biological and technical variation inherent in each technique.			
		data points in the Guinier plots (closed circles) were used in the fit. Non-linear data points in the Guinier plots (open circles) were ne criteria for excluding the non-linier data points were pre-established. No other data was omitted in this study.		
		pendent biological replicates were used in all experiments and indicated as n in figure legends, with all replications successful. Technical ication was performed in qPCR which was averaged before comparing biological replicates		
Randomization All	research material v	was homozygous, and therefore individual organisms were randomly distributed to control and treatment groups		
· ·	Experimenters were not blind to sample collection, but tubes were assigned numbers which were reconciled with sample names once molecular analysis was completed			
We require information f	rom authors about s	cific materials, systems and methods some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material tudy. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exper	imental syster	ns Methods		
n/a Involved in the st	tudy	n/a Involved in the study		
Antibodies		ChIP-seq		
Eukaryotic cell lines		Flow cytometry		
	and archaeology	MRI-based neuroimaging		
Animals and ot	her organisms			
Clinical data				
Dual use resea	rch of concern			
☐ X Plants				

Plants

Seed stocks All Lotus seeds were obtained from lotus base available at lotus.au.dk Line numbers are available in extended data file 2

Novel plant genotypes

The fun mutant was screened as described in methods from a population of Lotus individuals carrying randomly inserted LORE1 insertions. Insertion sites were characterised by insertion sequencing and PCR validation as described in methods

Authentication

Mutants were verified by PCR genotyping as described in the methods section using primers listed in extended data figure 2